STOCK TITAN
  1. Home
  2. Sec-filings
  3. ELVN
  4. [Form 4] Enliven Therapeutics, Inc. Insider Trading Activity

Enliven Therapeutics (NASDAQ: ELVN) CFO sells 6,018 shares after option exercise

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Enliven Therapeutics CFO Benjamin Hohl reported an option exercise and related share sales on July 17, 2026. He exercised stock options covering 1,072 shares of common stock at an exercise price of $2.48 per share and sold 6,018 common shares in open-market transactions pursuant to a Rule 10b5-1 trading plan adopted on March 18, 2026. Following the exercise, he held 84,966 stock options for Enliven common stock.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Hohl Benjamin
Role CHIEF FINANCIAL OFFICER
Sold 6,018 shs ($317K)
Approx. gross sale proceeds $317K
Approx. exercise cost $3K
Type Security Shares Price Value
Exercise Stock Option (right to buy) F1, F8 1,072 $0.00 $0.00
Exercise Common Stock F1, F2 1,072 $2.48 $3K
Sale Common Stock F1, F3, F2 324 $49.9715 $16K
Sale Common Stock F1, F4, F2 369 $51.4823 $19K
Sale Common Stock F1, F5, F2 2,564 $52.318 $134K
Sale Common Stock F1, F6, F2 2,638 $53.3825 $141K
Sale Common Stock F1, F7, F2 123 $53.8716 $7K
Holdings After Transaction: Stock Option (right to buy) — 84,966 shares (Direct); Common Stock — 46,054 shares (Direct)
Footnotes (8)
  1. F1. The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026.
  2. F2. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
  3. F3. This transaction was executed in multiple trades at prices ranging from $49.72 to $50.3778. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  4. F4. This transaction was executed in multiple trades at prices ranging from $50.765 to $51.7481. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  5. F5. This transaction was executed in multiple trades at prices ranging from $51.77 to $52.7695. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  6. F6. This transaction was executed in multiple trades at prices ranging from $52.77 to $53.7685. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  7. F7. This transaction was executed in multiple trades at prices ranging from $53.78 to $53.9781. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  8. F8. All of the shares subject to this option are fully vested and exercisable as of the date hereof.
Options exercised 1072.0000 shares Stock options for common stock exercised on 2026-07-17
Option exercise price 2.4800 USD per share Exercise price of stock option converted into common stock
Shares sold (total) 6018 shares Total Enliven common shares sold in open-market transactions on 2026-07-17
Weighted average sale price 1 49.9715 USD per share First reported tranche of common stock sales
Weighted average sale price 2 51.4823 USD per share Second reported tranche of common stock sales
Weighted average sale price 3 52.3180 USD per share Third reported tranche of common stock sales
Weighted average sale price 4 53.3825 USD per share Fourth reported tranche of common stock sales
Options held after exercise 84966.0000 options Stock options for common stock held directly after the reported exercise
Rule 10b5-1 trading plan financial
"were effected pursuant to a Rule 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock units (RSUs) financial
"Certain of these securities are restricted stock units (RSUs). Each RSU"
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
weighted average sale price financial
"The price reported above reflects the weighted average sale price."
contingent right financial
"Each RSU represents a contingent right to receive one share"
vesting schedule financial
"subject to the applicable vesting schedule and conditions of each RSU."
A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transactions did Enliven Therapeutics (ELVN) CFO Benjamin Hohl report?
CFO Benjamin Hohl reported exercising stock options for 1,072 shares at $2.48 per share and selling 6,018 shares of Enliven Therapeutics common stock in multiple open-market transactions on July 17, 2026, all under a pre-arranged Rule 10b5-1 plan.

How many Enliven Therapeutics (ELVN) shares did the CFO sell and at what prices?
Hohl sold a total of 6,018 Enliven Therapeutics common shares in several trades with weighted average prices of $49.9715, $51.4823, $52.3180, $53.3825 and $53.8716 per share, each executed in multiple smaller trades within stated price ranges.

Were the ELVN CFO’s transactions made under a Rule 10b5-1 trading plan?
Yes. The option exercise and all related sales were effected under a Rule 10b5-1 trading plan that Hohl adopted on March 18, 2026, as disclosed in the filing footnotes, indicating the trades followed a pre-established schedule.

What stock options did the Enliven Therapeutics (ELVN) CFO exercise?
Hohl exercised a Stock Option for 1,072 underlying shares of Enliven common stock at an exercise price of $2.4800 per share. The option was fully vested and exercisable and is scheduled to expire on August 2, 2031, according to the disclosure.

How many Enliven Therapeutics (ELVN) stock options does the CFO hold after these trades?
After the reported option exercise, Hohl held 84,966 stock options for Enliven Therapeutics common stock directly. This figure reflects the remaining options reported for the exercised grant following the 1,072-share exercise on July 17, 2026.

What are the restricted stock units (RSUs) mentioned in the ELVN Form 4 footnotes?
The filing notes that certain securities are restricted stock units (RSUs), where each RSU represents a contingent right to receive one share of Enliven’s common stock, subject to the specific vesting schedules and conditions of each RSU award.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hohl Benjamin
(Last)(First)(Middle)
C/O ENLIVEN THERAPEUTICS, INC.
205 PARK ROAD
(Street)
BURLINGAME CALIFORNIA 94010
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CHIEF FINANCIAL OFFICER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/17/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/17/2026M(1)1,072A$2.4852,072(2)D
Common Stock07/17/2026S(1)324D$49.9715(3)51,748(2)D
Common Stock07/17/2026S(1)369D$51.4823(4)51,379(2)D
Common Stock07/17/2026S(1)2,564D$52.318(5)48,815(2)D
Common Stock07/17/2026S(1)2,638D$53.3825(6)46,177(2)D
Common Stock07/17/2026S(1)123D$53.8716(7)46,054(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$2.4807/17/2026M(1)1,072 (8)08/02/2031Common Stock1,072$084,966D
Explanation of Responses:
1. The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026.
2. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
3. This transaction was executed in multiple trades at prices ranging from $49.72 to $50.3778. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
4. This transaction was executed in multiple trades at prices ranging from $50.765 to $51.7481. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
5. This transaction was executed in multiple trades at prices ranging from $51.77 to $52.7695. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
6. This transaction was executed in multiple trades at prices ranging from $52.77 to $53.7685. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
7. This transaction was executed in multiple trades at prices ranging from $53.78 to $53.9781. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
8. All of the shares subject to this option are fully vested and exercisable as of the date hereof.
/s/ Benjamin Hohl07/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR